Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

ClinicalTrials.gov ID: NCT03102034

Public ClinicalTrials.gov record NCT03102034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/ΔM2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

Study identification

NCT ID
NCT03102034
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
32 participants

Conditions and interventions

Interventions

  • D46/NS2/N/ΔM2-2-HindIII Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
6 Months to 24 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 5, 2017
Primary completion
May 24, 2018
Completion
May 24, 2018
Last update posted
Feb 7, 2022

2017 – 2018

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Usc La Nichd Crs Los Angeles California 90089
David Geffen School of Medicine at UCLA NICHD CRS Los Angeles California 90095-1752
Univ. of Colorado Denver NICHD CRS Aurora Colorado 80045
Emory University School of Medicine NICHD CRS Atlanta Georgia 30322
Rush Univ. Cook County Hosp. Chicago NICHD CRS Chicago Illinois 60612
Lurie Children's Hospital of Chicago (LCH) CRS Chicago Illinois 60614-3393
Johns Hopkins University Center for Immunization Research Baltimore Maryland 21205
SUNY Stony Brook NICHD CRS Stony Brook New York 11794
Jacobi Med. Ctr. Bronx NICHD CRS The Bronx New York 10461
St. Jude Children's Research Hospital CRS Memphis Tennessee 38105-3678

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03102034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 7, 2022 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03102034 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →